Inflammatory bowel disease: an overview of Chinese herbal medicine formula-based treatment

Shuo Yuan¹,², Qi Wang², Jiao Li²,³, Jia-Chen Xue²,³, You Li², Huan Meng², Xiao-Ting Hou², Ji-Xing Nan¹* and Qing-Gao Zhang¹,²,³*

Abstract

Inflammatory bowel disease (IBD) is a chronic recurrent inflammatory disease of the intestine, including Crohn’s disease (CD) and ulcerative colitis (UC), whose etiology and pathogenesis have not been fully understood. Due to its prolonged course and chronic recurrence, IBD imposes a heavy economic burden and psychological stress on patients. Traditional Chinese Herbal Medicine has unique advantages in IBD treatment because of its symptomatic treatment. However, the advantages of the Chinese Herbal Medicine Formula (CHMF) have rarely been discussed. In recent years, many scholars have conducted fundamental studies on CHMF to delay IBD from different perspectives and found that CHMF may help maintain intestinal integrity, reduce inflammation, and decrease oxidative stress, thus playing a positive role in the treatment of IBD. Therefore, this review focuses on the mechanisms associated with CHMF in IBD treatment. CHMF has apparent advantages. In addition to the exact composition and controlled quality of modern drugs, it also has multi-component and multi-target synergistic effects. CHMF has good prospects in the treatment of IBD, but its multi-agent composition and wide range of targets exacerbate the difficulty of studying its treatment of IBD. Future research on CHMF-related mechanisms is needed to achieve better efficacy.

Keywords: Autophagy, Chinese herbal medicine formula, Immunity, Inflammatory bowel disease, Intestinal mucosal barrier, Oxidative stress

Background

Inflammatory bowel disease (IBD) is non-specific colitis, mainly including ulcerative colitis (UC) and Crohn’s disease (CD), with symptoms such as abdominal pain, diarrhea, and weight loss [1]. Currently, the prevalence of IBD is on the rise worldwide, with a prevalence of 10–20% in developed countries and more severe in developing countries [2, 3]. Pharmacological treatment of IBD in modern society mainly uses drugs such as 5-aminosalicylates and immunosuppressive agents. However, these drugs have side effects such as drug resistance and intestinal flora dysbiosis, which seriously affect the prognosis of patients’ lives [4]. Therefore, it is vital to investigate the pathological mechanism of IBD and find new targets and drugs for IBD treatment. The interaction between genetic and environmental factors, immune dysfunction, intestinal flora dysbiosis, and impaired intestinal mucosal barrier function is currently the leading causes of IBD development.

With the continuous development of the global pharmaceutical industry, Traditional Chinese Medicine has received more and more attention. Most Chinese Herbal Medicine has a long history of clinical experience in the treatment guided by Chinese medical theory. Chinese
Herbal Medicine’s development and exploitation procedure are the opposite of chemical drug research, which mainly starts with clinical practice screening to identify candidate compounds and then clinical validation to enter the new drug development track for clinical research, production, and marketing [5]. The Chinese Herbal Medicine Formula (CHMF) has certain specificities and advantages compared with some Western medicines. CHMF is a formula composed of two or more medicinal flavors, with relatively prescriptive processing and usage methods, for relatively definite disease evidence and is the main component of Traditional Chinese Medicine prescriptions. CHMF has a complex chemical composition and pharmacological effects with multi-target medical characteristics [6].

It has been shown that the co-administration of Indirubin and Isatin, the co-administration of Astragalus membranaceus polysaccharides, and Codonopsis pilosula polysaccharides, as well as the administration of Fuzi-Ganjiang, can improve clinical symptoms in UC mice [7–9]. The remarkable therapeutic advantages of Chinese medicine for IBD have received increasing attention from scholars, and this article describes the progress of basic research achieved by CHMF in the treatment of IBD in recent years. The current use of CHMF for IBD treatment is mainly focused on improving intestinal mucosal barrier function, immunomodulation, and regulating oxidative stress.

**Intestinal mucosal barrier**

Patients with IBD have a damaged intestinal mucosal barrier, leading to abnormal cytokine secretion, intestinal mucosal atrophy, permeability changes, and intestinal flora displacement [4]. This may lead to recurrent inflammation and aggravation of inflammation. The intestinal mucosal barrier comprises four parts: mechanical barrier, chemical barrier, immune barrier, and biological barrier. If one of the barriers is damaged, it will lead to the destruction of the intestinal mucosal barrier, resulting in impairment of its function, induction of intestinal infection, and the occurrence of diseases such as IBD.

**Intestinal mucosal mechanical barrier**

The mechanical barrier is the intestinal mucosal epithelial structure, including the intestinal epithelial cells (IECs) and the connections between IECs, which absorb nutrients and exclude harmful substances outside the barrier. The intestinal mucosal epithelial cells and the tight junction (TJ) between the cells form the intestinal mucosal mechanical barrier. The integrity of the intestinal mucosal mechanical barrier is determined by the composition and function of IECs and TJs [10]. The disruption of TJ infiltrates harmful luminal molecules and disrupts the intestinal mucosal immune system and inflammation. Therefore, TJ can act as a trigger for the development of intestinal and systemic diseases [11]. The TJ comprises a family of cytoplasmic proteins, like ZO (zonula occludens proteins), transmembrane proteins (tricellulin, nectin, junctional adhesion molecules, occludin, and claudins), and cytoskeletal structures together. Occludin and claudins can regulate the function of the intestinal mucosal mechanical barrier by affecting TJ permeability [12]. Targeting the restoration of TJs integrity may become an effective way to treat and prevent IBD.

In dextran sulfate sodium (DSS)-induced UC mice, the QingBai decoction, Huang-Lian-Jie-Du Decoction, and Huangqin Decoction increased the expression of ZO-1 and Occludin in colonic mucosal [13–15]. Fang investigated the effect of Qing Hua Chang Yin on the loss of intestinal epithelial barrier integrity induced by lipopolysaccharide (LPS) in vitro using a Caco-2 cell model and found that Qing Hua Chang Yin could upregulate the mRNA and protein expression levels of Claudin-1 [16]. In addition, Sijunzi Decoction can also upregulate the level of Claudin-2 in the colon tissue of rats induced by a 2,4,6-trinitrobenzene sulfonic acid (TNBS) in vivo as an intestinal barrier protector [17].

**Intestinal mucosal chemical barrier**

The mucosal chemical barrier is less reported, but it also plays an essential role in IBD. The loose mucus layer covering the intestinal epithelial cells and the mucin in the mucus together constitute the intestinal mucosal chemical barrier [18]. Mucins can prevent pathogenic bacteria from invading and adhering to the intestine. Huang-Lian-Jie-Du Decoction can protect the intestinal mucosa by increasing the secretion of mucins [14].

**Intestinal mucosal microbial barrier**

In recent years, intestinal flora disorders have become an essential factor in the pathogenesis of IBD. The micro spatial structure of the intestinal commensal bacteria and the host constitutes the intestinal mucosal microbial barrier. Intestinal flora can interact with cells to promote barrier function through nutrient acquisition, energy and metabolic regulation, and cell proliferation [19]. The relationship between the intestinal flora and the organism’s autoimmune system coexists and influences each other. The imbalance of intestinal microbiology can lead to various inflammatory and metabolic diseases in the body [20]. It has been shown that during the active phase of IBD, there is intestinal flora dysbiosis and decreased species diversity within the organism [21]. CHMF can regulate intestinal flora disorders and maintain the homeostatic balance of intestinal flora [22]. Huang-Lian-Jie-du Decoction, Huangqin Decoction, and
*Pyungwi-san* can restore the balance of intestinal flora in UC mice by inhibiting the growth of intestinal pathogens and preventing the reduction of beneficial bacteria [23–25]. In DSS-induced UC rats, the ratio of Bacteroidetes to Firmicutes was elevated. This ratio decreased to normal levels with the use of Huai Hua San [26]. It has also been suggested that IBD is associated with Clostridium difficile (CDD) infection, resulting from dysbiosis of the intestinal flora. In contrast, *Pyungwi-san* normalizes the abundance ratio of Firmicutes/Bacteroidetes in the intestine and has some protective effect against DSS + CDD-induced colitis, which may be achieved by restoring the balance of the intestinal microbial community [27].

IBD can cause abnormal metabolic regulation in vivo. The resident intestinal flora can suppress the expression of pro-inflammatory cytokine genes by secreting short-chain fatty acids (SCFAs), vitamins, and other beneficial active metabolites [28]. Several metabolic pathways, including amino acids, fatty acids, and bile acids, are perturbed in IBD patients. Metabolomics characterizes the overall and dynamic changes in the type and concentration of endogenous small-molecule metabolites (e.g., amino acids, lipids, nucleosides) in the organism when disturbed by disease or drugs [29]. Subsequently, metabolomics can be correlated with genomic and proteomic results to facilitate the systematic study and comprehensive interpretation of disease mechanisms or drug mechanisms of action [30, 31]. Therefore, metabolomics is used to characterize the endogenous metabolic profiles of IBD patients and to reveal the critical metabolic pathways that are perturbed during the development and progression of IBD. It has important implications for the in-depth investigation of the pathogenesis of IBD and the search for new therapeutic targets for IBD. Hong analyzed the metabolic profile of UC rats by LC–MS/MS and identified a total of 36 differential metabolites involved in multiple metabolic pathways. Compound Sophorae Decoction could affect multiple metabolic pathways in TNBS-induced UC rats, thus diminishing their pathophysiological symptoms and obtaining positive therapeutic effects [32]. Huankuile Suspension inhibits inflammatory response and regulates bile metabolism, pyrimidine metabolism, purine metabolism, glutathione metabolism, and citric acid cycle in UC rats [33]. Huang-Lian-Jie-du decoction alleviates UC in mice by regulating arachidonic acid metabolism and glycerophospholipid metabolism [34]. *Astragalus membranaceus* polysaccharides and *Codonopsis pilosula* polysaccharides could upregulate the effects of isovaleric and butyric acids in SCFAs to improve clinical symptoms in mice with colitis [9]. Huangqin Decoction plays a crucial role in normalizing metabolic disorders by regulating the levels of amino acid, lipid, and fatty acid markers in UC rats [35, 36]. Rhubarb Peony Decoction increased the number of butyric acid-producing *Butyricicoccus pullicaecorum* and the level of SCFAs to restore intestinal function in UC mice. The dynamic changes of intestinal flora and host co-metabolites were detected by metabolomics to clearly demonstrate the metabolic status of intestinal flora in the host, which may provide clues and directions for studies such as the drug treatment mechanism IBD [37].

### Intestinal mucosal immune barrier

Gut-associated lymphoid tissue (GALT), secretory antibodies, and mesenteric lymph nodes (ETC) constitute the intestinal mucosal immune barrier, which can respond to antitoxins, antigens, and potentially harmful organisms [38]. GALT produces IgA, which forms the antigen complexes with antigenic material, binds to receptors on M cells, and antigens are transferred to the lamina propria and then presented to dendritic cells (DCs). Inflammatory DCs play an essential role in the pathogenesis of IBD, and Sishen Pill can modulate the interaction between inflammatory DCs and the gut microbiota to treat DSS-induced colitis [39].

### Immunity

#### T lymphocytes

The exact mechanism of cellular dysfunction leading to IBD is not fully understood. However, modulating the function of immune cells could be a powerful tool in the treatment of inflammatory diseases. The adaptation of T lymphocytes to the intestinal environment requires constant differentiation between natural stimuli from commensal flora, natural stimuli from food, and pathogens that need to be removed. T lymphocytes in the gut can be activated by environmental and other factors, causing genetic variants of intestinal defense defects or tolerance disruptions, such as intestinal infections or flora imbalances, triggering multiple immune disorders [40]. Therefore, T lymphocytes are the critical site of drug action for IBD treatment. The intestinal inflammatory infiltrate is mainly composed of CD4+ T cells, regulatory T cells (Tregs), and main memory T Cells (Tcm) [41]. There are several specific subpopulations of T helper cells: Th1, Th2, Th9, Th17, Th22, T follicular helper (Tfh), and several auto Tregs [41]. Th17 cells play an essential barrier role in the skin and intestinal mucosa. The resistance to bacteria and fungi is an essential driver of autoimmune disease, which often exacerbates disease when triggered in the autoimmune environment. The differentiation of Th17 is mainly driven by interleukin (IL)-6 and transforming growth factor (TGF)-β, which is further stabilized by paracrine signals such as IL-23 and IL-1β [42]. It is now generally accepted that the solid anti-inflammatory CD4+ T-cell, Tregs, are abundant in the intestine
In DSS-induced UC mice, Huangqin Decoction was able to increase the number of Tregs to alleviate the inflammatory effects [15]. The role of Tregs cells is mainly to suppress inflammation by suppressing T cells and regulating other immune cells in their environment, especially interconnected with Th17 cells in differentiation, which together maintain the body's balance of the immune microenvironment.

Once this balance is disrupted, multiple autoimmune diseases, including IBD, can occur [44]. In exploring the relationship between T lymphocytes and IBD, it has been found that Gegen Qinlian Decoction could restore the balance of Treg and Th17 cells in the colonic tissue of UC mice [45]. In TNBS-induced mouse mesenteric lymph node lymphocytes and lamina propria monocytes, Qingre Zaoshi Liangxue Decoction decreased the proportion of Th17 cells and increased the proportion of Treg cells [46]. Compound Sophorae Decoction can regulate the percentage of Th17 and Treg cells in the mesenteric lymph nodes of UC mice [47]. Furthermore, Bawei Xileisan restored the balance of Th17/Treg in monocytes [48]. The role of Tfh cells is to participate in B-cell differentiation and play a role in immunoglobulin production [48]. The role of Tfh cells is to participate in B-cell differentiation and play a role in immunoglobulin production [48]. The role of Tfh cells is to participate in B-cell differentiation and play a role in immunoglobulin production [48]. The role of Tfh cells is to participate in B-cell differentiation and play a role in immunoglobulin production [48].

**NF-κB**

The nuclear factor kappa B (NF-κB) family includes NF-κB1 (p50 and precursor p105), NF-κB2 (p52 and precursor p100), and related factor A, nuclear factor c-Rel, and related factor B. They all have a Rel homologous structural domain at the N terminus, which dimerizes with the DNA sequence that specifically binds to DNA sequences and activates or represses downstream transcription [50]. In the absence of external signal stimulation, the above proteins form homodimers or heterodimers and are strictly inhibited by the inhibitor of the NF-κB (IκB) family. They are regulated by the inhibitor of the NF-κB kinase (IKK) complex [51]. NF-κB is a crucial regulator of inflammation and can be activated by various stimulatory factors. The degradation of IκB translocates NF-κB to the nucleus and mediates the transcription of various target genes. Several pro-inflammatory factors encoded by the NF-κB signaling pathway promote inflammation-associated tissue damage and are associated with tumor development [52]. Huangkui Lianchang Decoction inhibits the NF-κB signaling pathway in DSS-induced ulcerative colitis [53]. Jian-Pi Qing-Chang Decoction and Tou Nong San can improve mucosal inflammatory response and intestinal epithelial barrier function through the NF-κB pathway. Also, their anti-inflammatory effects are associated with NF-κB regulation [54–57].

TOLL-like receptors (TLRs) are cellular transmembrane receptors in the natural immune system. TLRs can bind to pathogen recognition pattern molecules, activate downstream signaling molecules, and ultimately trigger the expression of inflammatory mediators, serving as a link between natural immunity and acquired immunity. TLR4 is a subtype of the TOLL receptor family, and myeloid differentiation factor 88 (MyD88) is the main junction protein in the TLR4 signaling pathway. The interaction between TLR4 and MyD88 ultimately mediates the innate immune response and inflammatory response against pathogenic bacteria [58]. It was found that the TLR4 mediated signaling pathway is involved in the development of UC. TLR4 is a transmembrane receptor in the natural immune system, which recognizes the corresponding ligand and then binds to it to initiate signal transduction, leading to NF-κB activation and release of intestinal inflammatory mediators [59]. Gegen Qinlian Decoction can inhibit the TLR4/NF-κB signaling [60]. Kuijieyuan Decoction ameliorates intestinal barrier damage in ulcerative colitis by affecting TLR4-dependent NF-κB signaling [61].

Myosin light chain kinase (MLCK) is a calmodulin-dependent serine/threonine-specific protein kinase whose primary function is to phosphorylate myosin light chain (MLC) and activate myosin heavy chain adenylate triphosphatase. MLCK mediates the sliding of skeletal protein microfilaments, causing cell contraction and eventually the formation of cellular gaps [62]. A variety of signaling pathways are involved in the activation of MLCK, mainly through the mitogen-activated protein kinase (MAPK) pathway of extracellular regulated protein kinase (ERK) 1/2, P38, c-Jun N-terminal kinase (JNK) pathway, as well as inflammation-related pathways involved in cell proliferation and apoptosis [63]. In TNBS-induced UC rats, Bu-Zhong-Yi-Qi Granule can regulate the secretion of some inflammatory cytokines and improve TJ integrity through TLR4/NF-κB/MLCK pathway [64]. Sijunzi Decoction could reduce the levels of NF-κB p65 and MLCK [17]. In addition, Shen-Ling-Bai-Zhu-San attenuated DSS-induced UC mice via the MAPK/NF-κB signaling pathway [65]. NEMO is encoded by the B cell-encoded κ light chain polypeptide repressor gene (IkBKG) [66], and in 1998, Brott cloned the mammalian homolog of the Nemo gene named Nemo-like kinase (NLK) [67]. It has been confirmed that NLK is a highly conserved MAPK-like kinase during evolution and has a significant reference value for disease prognosis [68]. Sishen Pill can inhibit NF-κB activation by suppressing the NEMO/NLK signaling pathway and plays a vital role in treating chronic colitis [69].
The assembly of NOD-like receptor protein 3 (NLRP3) requires the involvement of the sensor NLRP3 pattern recognition receptor, apoptosis-associated speck-like protein containing a CARD (ASC), and the effector protein caspase-1 are involved, which widely presented in various immune cells when the disease occurs [70]. Microbiol molecules require the activation of NLRP3 or some signaling through NF-κB proteins, which induce NLRP3 to indirectly promote the expression of the assembled inflammasome complex [71]. Both Jia-weishaoyao Decoction and Pyungwi-san can inhibit the NLRP3 inflammasome, and the NF-κB pathway to alleviate DSS-induced UC [72, 73].

PI3K is an intracellular phosphatidylinositol kinase. Upon the activation of PI3K, PIP3 acts as a second messenger and binds to regional proteins of Akt. This leads to the acquisition of Akt activity, which is involved in cell growth, cell development, and apoptosis through the regulation of downstream proteins [74]. Akt is a serine/threonine kinase, also known as protein kinase B or PKB, which is a target of action downstream of the PI3K pathway, and its anti-apoptosis mechanism is phosphorylation of target proteins by multiple downstream pathways. The activated Akt is involved in activating and inhibiting multiple targets after phosphorylation, enabling cell survival, growth, and proliferation through multiple mechanisms [75]. Zuojin Pill can modulate the crosstalk between intestinal microbes and Treg cells to attenuate DSS-induced colitis through PI3K/Akt signaling pathway [76]. Sishen Pill alleviates DSS-induced colitis, which may be related to inhibiting the PI3K/Akt signaling pathway [77]. Xianglian Pill can block the activation of the PI3K/Akt/mTOR pathway, inhibit the secretion of pro-inflammatory cytokines, and repair the dysfunction of the intestinal epithelial barrier to enhance autophagy [78]. Upon activating the PI3K/Akt pathway, activated Akt inhibits phosphorylation degradation of protein IκB kinase by enhancing NF-κB, which subsequently leads to NF-κB activation. Huangqin Decoction can improve DSS-induced colitis by modulating the intestinal microbiota and inhibiting the PI3K/Akt/HIF-1α and NF-κB pathways [79]. Kuijiejuyuan Decoction ameliorates intestinal barrier damage in ulcerative colitis by affecting TLR4-dependent PI3K/AKT/NF-κB signaling pathway [61].

**JAK2/STAT3**

The JAK/STAT3 signaling pathway is composed of Janus kinase (JAK), tyrosine kinase receptor, and Signal Transducer and Activator of Transcription 3 (STAT3), which are essential in cell growth, cell proliferation, cell invasion, cell metastasis, and regulation of apoptotic processes [80]. The STAT family, a group of intracellular proteins that signal and activate transcriptional functions, contains seven members (STAT1-4, 5A, 5B, and 6). The JAK2/STAT3 signaling pathway is an important pathway mediating the signaling of numerous cytokines and inflammatory mediators, closely associated with the expression of inflammatory immune factors associated with tumor necrosis factor-α (TNF-α), IL-6, IL-17, and IL-22 [81]. The activation of JAK2 will phosphorylate tyrosine residues, which are later bound to the receptor and phosphorylated by STAT3. Phosphorylated JAK2 forms a dimer or heterodimer with phosphorylated STAT3 and ectopic to the nucleus, affecting the transcription of downstream genes and the expression of inflammatory factors [82]. Gegen Qinlian Decoction and Huanglian Jiedu Decoction reduce inflammation by inhibiting JAK2/STAT3, decrease inflammation by inhibiting JAK2/STAT3 signaling, and has a protective effect on UC [45, 83]. Qingre Zaoshi Liangxue Decoction, Pien Tze Huang, and Baitouweng Decoction significantly improved the inflammatory symptoms in mice with acute colitis, and the latent mechanism may be related to various signaling pathways, including regulation of gut microbiota and inflammatory signaling pathways, such as IL-6/STAT3 [46, 84, 85].

**Notch**

The Notch pathway is highly conserved in various organisms, involved in developing almost all organ systems, and regulates tissue homeostasis after development. The Notch signaling pathways include Notch ligands (Delta-like ligands 1, 3, 4, Serrate-like ligands Jagged1, Jagged2), Notch1, Notch2, Notch3, Notch4, Notch DNA binding proteins, immunoglobulin κJ region recombinant signaling proteins and effector molecules (Hes, Hcy, Herp) [86]. The Notch signaling pathway activates Notch receptors on the cell surface upon binding to ligands, inducing protein hydrolysis cleavage. The intracellular segment of Notch is released into the nucleus and binds to the transcriptional repressor RBP-Jκ to activate the transcription of target genes, which can regulate cell proliferation, cell differentiation, and apoptosis [87]. In the DSS-induced UC mice, Gegen Qinlian Decoction maintains mucosal homeostasis through bidirectional regulation of Notch signaling, thereby restoring colonic epithelial function [88]. Compound Sophorae Decoction modulates the Notch signaling, promotes altered macrophage phenotype, and enhances colonic mucosal barrier function [89]. QingBai Decoction inhibited the effects of NF-κB and Notch signaling on the inflammatory cascade, which effectively alleviated intestinal inflammation and mucosal barrier function in DSS-induced UC mice [13].
Others

TLRs are vital pattern recognition receptors that can lead to uncontrolled inflammatory responses in case of excessive activation [90]. IL-1 receptor-associated kinase (IRAK) mediates multicellular receptor signaling, including TLRs, and has an essential regulatory role in various inflammatory cell signaling networks [91]. Tiaoxyan Extract Tablets improved colonic inflammation in rats with chronic colitis, and this effect may be achieved by activating lysosomes in macrophages through inhibition of the TLR9/MyD88/IRAK signaling pathway [92].

The primary biological function of Oncostatin-M (OSM) is to inhibit the growth of a variety of tumor cells and to induce the differentiation of specific tumor cells. OSM is a promising cytokine because it can significantly inhibit the growth and induce the differentiation of tumor cells through a variety of different pathways.

The Oncostatin-M receptor (OSMR) is widely distributed on the surface of many tumor cells, endothelial cells, and epithelial cells [93]. The expression of OSM and OSMR is increased in intestinal tissues of patients with IBD, which leads to increased intestinal inflammation. Therefore, OSM and OSMR have become markers in IBD diagnosis [94]. Feiyangchangweiyan Capsule affects UC by inhibiting the OSM/OSMR pathway and regulating inflammatory factors to improve intestinal flora [95].

The Wnt signaling pathway regulates the growth and development of the body, which maintains the normal physiological functions of many tissues and organs, and its abnormal activation or inhibition contributes to the development of many diseases. The Wnt/β-catenin signaling pathway is one of the most important signaling pathways that significantly impact the progression of multiple diseases. Its central role is to activate the proliferation of intestinal stem cells and inhibit the differentiation of intestinal stem cells from maturing cell types [96, 97]. Sishen Pill effectively attenuated TNBS-induced colitis, which inhibited the Wnt/β-catenin signaling pathway [77].

Oxidative stress

It has been reported that the concentration of reactive oxygen species (ROS) in intestinal cells increases during chronic inflammatory and recurrent immune responses in the gut as the disease develops [98]. ROS regulates cellular regulation by oxidizing DNA, proteins, lipids, and other cellular structures. In order to protect biological systems from damage caused by excessive ROS, the cellular antioxidant system is activated and thus regulates ROS production. ROS levels were significantly increased in the colon of DSS-induced UC mice. Gegen Qinlian decoction and Sanhuang Shu'ai decoction reduced ROS concentrations and thus prevented the onset and progression of the disease [60, 99]. Nuclear factor E2-related factor 2 (Nrf2) is an important transcription factor regulating the cellular oxidative stress response and is a central regulator in maintaining intracellular redox homeostasis. Nrf2 regulates constitutive and inducible expression of a series of antioxidant proteins to mitigate reactive oxygen species and electrophilic body-induced cellular damage and maintain tissue cell redox dynamic homeostasis [100]. Huang-Lian-Jie-Du Decoction can effectively alleviate DSS-induced UC mice by inhibiting the NF-κB signaling pathway, activating the Nrf2 signaling pathway, and enhancing intestinal barrier function [14]. Superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH) are downstream enzymes of the Nrf2 pathway that convert oxygen radicals into hydrogen peroxide and rapidly break them down into the water, effectively preventing tissue cells from being damaged by peroxides [101]. SOD can scavenge superoxide anions produced in the body. CAT is a crucial component of the enzyme system in the body's antioxidant system, which can scavenge free radicals in synergy with SOD, and GSH can protect cell membrane structure and function from oxidative damage by hydrogen peroxide. All SOD, CAT, and GSH have essential roles as antioxidants, and when their levels and activity are reduced, they lead to the accumulation of free radicals [102]. Myeloperoxidase (MPO) is a crucial peroxidase produced by neutrophil asplenophil granules, and its activity level reflects the degree of neutrophil infiltration. Malondialdehyde (MDA) is the end product of the lipid peroxidation reaction between ROS and unsaturated fatty acids on the cell membrane, and its level can indirectly reflect the degree of lipid peroxidation [102]. Gegen Qinlian Decoction and Kuijieyuan Decoction reduced MDA and MPO levels and increased SOD, GSH, and CAT levels, showing a protective function against UC animal models [60, 61].

Novel Chinese herbal medicine formula

As a unique health resource in China, Chinese Medicine is increasing attention worldwide. In novel drug development, Chinese Herbal Medicine and natural products have become an essential source of innovative drug development. At present, for the research and evaluation of new drugs in different categories of Chinese Medicine and natural drugs, based on many years of experience in new drug research in Chinese medicine, many people have proposed ideas for the research and evaluation of drugs in different categories originating from classical formulas, and combined with basic research to carry out innovative research in various aspects.

Qingre Jianpi Decoction, the classically formulated optimized Qingchang Suppository, and the simplified
prescription Suqing Pill reduced the secretion of inflammatory cytokines and exerted anti-inflammatory effects in UC treatment [103–105]. The Chinese herbal standardized product Guchang Capsule, Semi-bionic Extraction of compound Turmeric, Modified Pulsatilla Decoction, the functional beverage Ampelopsis gos-sedentata, and Guchang Zhixie Pill can all exert protective effects against IBD via the NF-κB signaling pathway [106–110].

Chemokine receptor 3 (CXCR3) is a specific binding protein that inhibits the endogenous chemokine IP10, and the IP10/CXCR3 axis plays a vital role in the pathogenesis of childhood IBD, and inhibition of IP10 may alleviate the clinical symptoms of UC [111]. CXCR3 is activated once it binds to IP10 and contributes to its transfer to the inflammatory localization for further effects. The large amount of inflammatory cytokines produced by local inflammation of intestinal mucosa stimulates IP10 to recruit more inflammatory cells to form a cascade response and aggravates the damage of the intestinal mucosal barrier [112]. Qingchang Wenzhong Decoction was able to downregulate IP10/CXCR3 axis-mediated inflammatory response, improve DSS-induced UC in rats, and maybe a new UC therapy [113]. Aquaporins (AQPs) are essential proteins in the body’s aqueous metabolism process, mediating the transport of water molecules along an osmotic gradient across cell membranes and mediating the transport of water molecules across different cell membranes [114]. AQPs are mainly involved in regulating urine concentration and fluid permeation in humans [115]. Ershen Pill Extract effectively improved diarrhea in rats by improving the synthesis of AQP3 in the colon [116]. In DSS-induced colitis, the increase in vascular permeability precedes the increase in intestinal epithelial permeability. Qingchang Suppository can reduce colonic vascular permeability and improve vascular endothelial barrier function by modulating the VEGF/HIF-1α signaling pathway [117]. In addition, some novel herbal combinations play an essential role in IBD. The use of Qingchang Suppository reduced colonic tissue edema, vascular congestion, and inflammatory cell infiltration [117]. Costus root granules significantly improved inflammation and apoptosis in the colonic epithelium by modulating the transforming growth factor (TGF)-β-mediated PI3K/AKT signaling pathway [118]. Xinhuang Tablets alleviated DSS-induced UC in mice by increasing intestinal epithelial Tj expression [119]. Composite Sophora Colon-Soluble Capsule also showed significant effects on UC from restoring intestinal microbiota and intestinal immune homeostasis [120].

The CHMF prepared by different methods can provide vital information for further mechanistic exploration of traditional prescriptions, contributing to the rational application of herbal compounding in modern applications or scientific research and improving human knowledge of herbal compounding. Banxia Xiexin Decoction is widely used in modern clinical practice. Both modern and ancient extraction methods can alleviate the severity of UC rats to different degrees [121]. The differences in the efficacy of the five Ganjiang Decoction extracts on DSS-induced UC in mice were closely related to the extraction methods. The study by Wei improved the extraction process of Ganjiang Decoction, which provided the basis for the process of enteric preparation and offered new ideas for the compounding of Chinese Herbal Medicines [122]. These Novel Chinese Herbal Medicine Formulas provide reference and reference for the development of new drugs in Chinese Medicine and natural products, intending to improve the efficiency and success rate of new drug development and enhance the development of new products.

Conclusions

The development of new drugs for CHMF is a crucial area of modern research in Chinese medicine. Chinese medicines, especially CHMF, are different from chemical, biological, and botanical drugs. Due to the complexity of the pharmacological substances and targets or links contained in CHMF, it poses a great difficulty for new drug development, but at the same time, it also has significant room for innovation. At present, the clinical treatment of IBD is mainly based on immunosuppressive drugs or hormone therapy, and the use of these drugs is strictly regulated, which is prone to adverse reactions and drug resistance if used irregularly. Table 1 shows the targets of the Chinese Herbal Medicine Formula in attenuating IBD. We hope to explore the association between CHMF and IBD to find new ideas for new drug development. At present, we should be oriented to highlight the characteristics and advantages of CHMF efficacy, fully utilize and draw on modern biotechnology, and thoroughly study the scientific and technological issues related to CHMF development. The level of knowledge of CHMF pharmacological substances and mechanisms of action should be further understood to contribute to creating high-level new drugs and provide new directions and ideas for the treatment of IBD.

In the West, biological agents are the fastest-growing segment of the prescription drug market and cost thousands of dollars per patient per year to treat IBD. There is a need to reconcile the most appropriate treatment for these patient populations from the perspectives of both disease presentation and cost. In developing countries, healthcare systems and indeed the patients struggle to afford such expensive treatments [123].
Table 1 The targets of the Chinese Herbal Medicine Formula in attenuating IBD

| Chinese herbal medicine formula                  | Components                                                                 | Experiment models          | Targets                                                                                                                                                                                                 | References |
|-------------------------------------------------|----------------------------------------------------------------------------|-----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Indirubin and Isatin                            | *Isatis indigotica* Fort., *Baphicacanthus cusia* (Nees) Bremek. and *Polygonum tinctorium* Ait | DSS-induced UC mice        | Reduce pro-inflammatory mediators and MPO, increase anti-inflammatory cytokines and Foxp3, inhibit CD4+ T cell infiltration, inhibit oxidative stress and epithelial cell apoptosis, inhibit NF-κB and MAPK pathways | [7]        |
| Fu-Fi-Ganjiang                                   | *Aconitum carmichaelii* Debeaux and *Zingiber officinale* Roscoe           | DSS-induced UC mice        | Inhibit MPO and inflammatory cytokines, inhibit the activation of MAPK, NF-κB and STAT3 signaling pathways                                                                                              | [8]        |
| Astragalus membranaceus polysaccharides and Codonopsis pilosula | Total polysaccharides of *A. membranaceus* extractum and the *C. pilosula* extractum | DSS-induced UC mice        | Rebuild immune balance, alleviate colonic mucosal damage, activate AhR, up-regulate isovaleric acid and butyric acid, and restore intestinal flora structure                                                      | [9]        |
| QingBai decoction                               | *Indigowoad Leaf*, *Amur Cork-tree Bark*, *Lightyellow Sophora Root*, *Coix Seed*, *Cuttlebone* | DSS-induced UC mice        | Up-regulate the expression of tight TJs and mucus 2, reduce the production and secretion of pro-inflammatory cytokines, and modulate NF-κB and Notch pathways                                                   | [13]       |
| Huang-Lian-Jie-Du Decoction                     | *Coptidis Rhizoma*, *Scutellariae Radix*, *Phellodendri Chinensis Cortex* and *Gardeniae Fructus* | DSS-induced UC mice        | Inhibit NF-κB signaling pathway, activate Nrf2 signaling pathway, enhance intestinal barrier, inhibit NF-κB signaling pathway, activate NF-κB signaling pathway, enhance intestinal barrier function, inhibit the growth of intestinal pathogens, prevent the reduction of beneficial bacteria, correct the dysfunction of intestinal flora | [14, 24, 34, 83] |
| Huangqin Decoction                              | *Scutellaria baicalensis* Georgi, *Paeonia lactiflora* Pall., *Glycyrrhiza uralensis* Fisch., and *Ziophus jujuba* Mill | DSS-induced UC mice        | Inhibit inflammation, alter gut microbiota, modulate SCFAs, prevent cellular damage caused by oxidative stress, inhibit Ras-P13K-Akt-HIF-1α and NF-κB pathways                                                 | [15, 23, 35, 36, 79] |
| Qing Hua Chang Yin                              | *Coptis chinensis* Franch., *Herba et Gemma Arctii Aegyptiacae*, *Radix Sanguisorbae*, *Magnolia officinalis*, *Radix Paeoniae Rubra*, *Elettaria cardamomum*, *Semem Cocos*, *Artemisia capillaris* Thund., *Semem Dolichoris Album*, *Herba Eupatori* Fortunei and *Poria cocos* | LPS-induced Caco-2 cell | Regulate TJs protein expression, protect intestinal epithelial barrier integrity after inflammatory injury                                                                                           | [16]       |
| Sijunzi Decoction                               | *Ginseng Radix et Rhizoma*, *Codonopsis pilosula*, *Atractylodes Macrocephalae* Rhizoma, *Poria*, and *Glycyrrhizee Radix et Rhizome Preparaticum Melle* | TNBS-induced UC mice       | Claudin-2, NF-κB and MLCK signaling pathway                                                                                                                                                          | [17]       |
| Pyungwi-san                                     | *Citri Pericarpium* peel, *glycyrrhizin*, *magnolol*, *Rhizoma Atractylodes Macrocephalae* | DSS-induced UC mice        | Modulate TJ protein, ameliorate pro- and anti-inflammatory cytokines, modulate gut microbiota, regulate TLR4 and PPARγ expression, inhibit NF-κB pathway and inhibit the activation of NLRP3 inflammasome | [25, 27, 73] |
| Chinese herbal medicine formula          | Components                                                                 | Experiment models                  | Targets                                                                                                               | References |
|-----------------------------------------|---------------------------------------------------------------------------|------------------------------------|----------------------------------------------------------------------------------------------------------------------|------------|
| Huai Hua San                            | Flos Sophorae (the dried flower bud of Sophora japonica L.), Cacumen Platycladi (the dried branches and leaves of Platycladi orientalis (L.) Franco), Fructus Auranti (the dried immature fruit of Citrus aurantium L.) and Herba Schizonepetae (the dried overground parts of Schizonepeta tenuifolia Briq.) | DSS-induced IBD rats              | Improve dysbiosis of the microbiome at the taxonomic level                                                            | [26]       |
| Compound Sophorae Decoction             | Radix sophorae flavescent, Radix sanguisorae, Rhizoma bletillae, Radix glycyrrhiza, and Indigo naturalis | TNBS-induced UC rats, DSS-induced IBD mice | Regulate the levels of metabolic biomarkers, reduce epithelial cell apoptosis, promote epithelial cell regeneration, up-regulate TJs expression and MUC2 secretion, modulate Notch signaling, reduce M1/M2 ratio, reduce inflammatory factors, and regulate Th17/Treg balance | [32, 47, 89] |
| Huankuile Suspension                    | Trukish galls, Coptis chinensis, pomegranate flower, amber, tabasheer and plantain herb | TNBS-induced UC rats              | Reduce pro-inflammatory cytokines, modulate bile metabolism, pyrimidine metabolism, purine metabolism, glutathione metabolism and citric acid cycle | [33]       |
| Rhubarb Peony Decoction                 | Rhei Radix et Rhizoma, Moutan cortex, Persicae semen, Natrii sulfas, and Benincasae semen | DSS-induced UC mice              | Altered gut microbiota, restored SCFA content in the gut, and modulate the ratio of Th17 cells to Treg cells          | [37]       |
| Sishen Pill                             | Semen psoraleae, Fructus evodiae, Semen myristicae and Schisandra chinensis | DSS-induced UC mice, TNBS-induced UC rats | Effectively control T eff cells in peripheral blood, inhibit P38/Akt signaling pathway, modulate the interaction between inflammatory DCs and gut microbiota, inhibit Wnt/β-catenin signaling pathway, inhibit the activation of NF-κB by NEMO/NLK signaling pathway | [39, 49, 69, 77] |
| Gegen Qinlian Decoction                 | Berberine, Baicalin, and Puerarin                                         | DSS-induced UC mice              | Inhibit IL-6/JAK2/STAT3 signaling, restore Treg and Th17 cell balance, reduce phagocytic cell differentiation, promotes CBC proliferation, reduce Notch-activated Hes1 protein in HT29 and FHC cells, and increase Notch inhibition Hes1 protein in cells, inhibit TLR4/NF-κB signaling and enhance antioxidant effects | [45, 60, 88] |
| Qingre Zaoshi Liangxue Decoction        | Sophora flavescens Aiton., Bletilla striata Rchb. f., Glycyrrhiza uralensis Fish., Coptis chinensis France., Baphicacanthus cusia (Nees) Bremek | TNBS-induced UC mice              | Decrease FICZ concentration and AHR signaling in the colon, decrease expression of IL-6, STAT3 and RORγt, increase expression of FOXP3, decrease the proportion of Th17 cells and increase the proportion of Treg cells | [46]       |
| Bawei Xileisan                          | Watermelon frost, calcite, cow gallstone, pearl powder, borax, borneol (Dryobalanops aromatica Gaertn. f.), ammonium chloride, and Indigo naturalis | DSS-induced UC mice              | Restore Th17/Treg balance, improve fecal lactobacillus levels, and protect gut microbiota                               | [48]       |
Table 1 (continued)

| Chinese herbal medicine formula | Components | Experiment models | Targets | References |
|---------------------------------|------------|-------------------|---------|------------|
| Huangkui Lianchang Decoction   | *Abelmoschus manihot* (L.) Medik, *Euphorbia humifusa* Willd., *Pennisetum rorum*, *Lithospermum erythrorhizon* Siebold & Zucc., *Rubia cordifolia* L., and *Rhus chinensis* Mill | DSS-induced UC mice | Alleviate colon pathological damage, reduce MPO and SOD activities, and inhibit NF-κB signaling pathway | [53] |
| Tou Nong San                   | *Radix astragali*, *Angelica sinensis*, *Ligusticum*, *Spina Gleditsiae*, and pangolin scales | TNBS-induced UC rats | Inhibit NF-κB signaling pathway and regulate pro-inflammatory cytokines | [55] |
| Jian-Pi Qing-Chang Decoction   | *Astragalus*, *Codonopsis pilosula*, *Portulaca oleracea*, *Sanguisorba officinalis*, *Notoginseng*, *Bletilla striata*, *Radix Aucklandiae*, and *Licorice* | DSS-induced UC mice | Improve mucosal inflammatory response and intestinal epithelial barrier function through NF-κB/HIF-1α signaling pathway, reduce the expression of IL-1β, IL-8 and TNF-α, activation of NF-κB and phosphorylation of IkB were significantly inhibited | [56, 57] |
| Kuijeyuan Decoction            | *Astragalus mongholicus* Bunge, *Hedyotis diffusa* Willd., *Oursinum undulatum* (Nutt.) Spreng, *Oursinum setosum* (Willd.) M. Bieb., *Pulsatilla vulgaris* Mill, *Prunella vulgaris* L. subsp. *Vulgaris*, *Coptis chinensis* Franch, *Polygonum cuspidatum* Sieb. et Zucc., *Atractylodes lancea* (Thunb) DC and *Glycyrrhiza glabra* L. | DSS-induced UC rats | Inhibit TLR4/NF-κB signaling pathway, inhibit PI3K/AKT/NF-κB signaling pathway and oxidative stress | [61] |
| Bu-Zhong-Yi-Qi Granule          | *Astragalus*, *Codonopsis pilosula* (Franch.) Nannf., *Liquorice*, *Atractylodes macrocephala*, Tangerine peel, Cohosh, Bupleurum, Angelica, Zingiber officinale Roscoe, and Jujube | TNBS-induced UC rats | Restore the expression of TJ protein and regulate the secretion of some inflammatory cytokines through the TLR4/NF-κB/MLCK pathway | [64] |
| Shen-Ling-Bai-Zhu-San           | *Panax ginseng* C. A. Mey., *Poria cocos* (Schw.) Wolf, *Atractylodes macrocephala* Koidz., *Dioscorea opposita* Thunb., *Dolichos lablab* L., *Nelumbo nucifera* Gaertn., *Coix lacryma-jobi* L. var. *mayuen. (Roman.) Stapf, *Amomum volatum* Lour., *Platyodon grandiflorum* (Jacq.) A. DC, and *Glycyrrhiza glabra* L. | DSS-induced UC mice | Inhibit MAPK/NF-κB signaling pathway | [65] |
| Jiaweishaoyao Decoction         | *Radix Et Rhizoma Glycyrrhizae*, *Semen Arecae*, *Magnolia officinalis* Rehd et Wils, *Catacus pinatifida* Bunge, *Radix Et Rhizoma Rhei*, *Massa Medicata Fermentata*, *Radix Paeoniae Alba*, and *Radix Angelicae Sinensis* | DSS-induced UC mice | Inhibit NLRP3 inflammasome and NF-κB pathway | [72] |
| Zuojin Pill                     | *Coptis chinensis* and *Evodia rutaecarpa* | DSS-induced UC mice | Regulate gut microbiota, improve CD4⁺/CD25⁺/Foxp3⁺ and PD-1⁺ Treg cells, inhibit PI3K/Akt signaling pathway | [76] |
| Chinese herbal medicine formula     | Components                                      | Experiment models          | Targets                                                                                                                                                                                                 | References |
|-----------------------------------|------------------------------------------------|-----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Xianglian Pill                    | *Coptidis Rhizoma* and *Aucklandiae Radix*     | DSS-induced UC mice         | Inhibit the secretion of pro-inflammatory cytokines, repair the dysfunction of the intestinal epithelial barrier, enhance autophagy, block the activation of the PI3K/Akt/mTOR pathway, weaken the protective effect of XLP on colitis, block the activation of PI3K/Akt/mTOR signaling pathway to promote autophagy | [78]       |
| Pien Tze Huang                    | Moschus, *Calculus bovis*, *Snake gall* and *Radix notoginseng* | DSS-induced UC mice         | Suppress levels of inflammatory biomarkers and inhibit IL-6/STAT3 signaling, improve gut microbiota                                                                                                                                                             | [84]       |
| Baitouweng Decoction              | *Radix pulsatilla*, *Cortex phellodendri*, *Rhizoma coditidis*, and *Cortex fraxini* | DSS-induced UC mice         | Regulate gut microbiota and IL-6/STAT3 inflammatory signaling pathway                                                                                                                                                                                      | [85]       |
| Tiaochang Xiaoyan Extract Tablets | *Radix Astragali*, *Lindera aggregata*, *Rhizoma coditidis*, *Oldenlandia diffusa* and *coix seed* | TNBS-induced UC rats        | Repair of colonic mucosal damage, reduce inflammation, increase lysosomal activity of macrophages, and decreased DAI in rats with colitis, improved colonic inflammation and infiltrate CD11c⁺ macrophages in rats with chronic colitis, and inhibit TLR9/MyD88/IRAK signaling pathway | [92]       |
| Feyangchangweiyan Capsule         | *Euphorbia hirta* L., *Polygonum chinense* L., and *Ilex rotunda* Thunb. | DSS-induced UC mice         | Inhibit OSM/OSMR pathway and modulate inflammatory factors, modulate gut microbiome composition                                                                                                                                                               | [95]       |
| Sanhuang Shu’ai decoction         | *Coptidis Rhizoma*, *Scutellariae Radix*, *Phellodendri Chinensis* *Cortex*, and *Artemisiae Argyi Folium* | DSS-induced UC mice         | Reduce oxidative stress, modulate gut microbiota, reduce inflammatory mediators and cytokines                                                                                                                                                                       | [99]       |
| Qingre Jianpi Decoction           | *Radix Astragali Mongolic*, *Rhizoma Coptidis*, *Herba Violae Philippicae*, *Radix Paeoniace Alba*, *Semen Alpiniae Katsumadai*, *Radix Notoginseng*, *Semen Plantaginis* and *Semen Myristicae* | DSS-induced UC mice         | Reduce the secretion of inflammatory cytokines, inhibit the activation of the NLRP3 inflammasome, and inhibit the inflammatory infiltration of immune cells                                                                                                                                 | [103]      |
| Qingchang Suppository             | *Radix Notoginseng*, *Indigo Naturalis*, *Gallnut*, *Herba Portulacaete* and *borneol* | TNBS-induced UC rats        | Improve colonic hypoxia, reduce the expression of VEGF, HIF-1α and iNOS, reduce colonic VP mediated VEGF/HIF-1α signaling pathway to improve vascular endothelial barrier function, and inhibit JAK2/STAT3 pathway | [104, 117] |
| simplified prescription Suqing Pill | *Lonicera japonica* Thunb., *Forsythia suspensa* (Thunb.) Vahl., *Taraxacum mongolicum* Hand. -Mazz., *Sanguisorba officinalis* L., *Trichosanthes kirilowii* Maxim., *Angelica dahurica* (Fisch. ex Hoffm.) Benth. et Hsok. El., *Rehmannia glutinosa* L., *Lobeliae philippicae* Radix, *Semen Alpiniae Katsumadai*, *Radix Notoginseng*, *Semen Plantaginis* and *Semen Myristicae* | DSS-induced UC mice         | Reduce the level of inflammatory factors, increase the level of anti-inflammatory cytokines, down-regulate oxidative factors                                                                                                                                 | [105]      |
Table 1 (continued)

| Chinese herbal medicine formula | Components                                                                 | Experiment models       | Targets                                                                                                           | References |
|---------------------------------|-----------------------------------------------------------------------------|-------------------------|-------------------------------------------------------------------------------------------------------------------|------------|
| Guchang Capsule                 | Halloysite, Coptis, Phellodendron amurense, Myrobolan, Nutmeg, Cortex Magnoliaceous officinalis, Fructus Evodiae, Qu Jian, Cinnamon, Rhizoma Zingiberis, Chinese Prickly Ash, Liquigumum wallichii, Concha Ostreae, Gallnut, and Dark Plum Fruit | DSS-induced UC mice     | Inhibit NF-κB activation in macrophages and reduce pro-inflammatory cytokine production                          | [106]      |
| Semi-bionic Extraction of compound Turmeric | Curcuma wenyujin Y., H. Chen et C. Ling, Terminalia chebula Retz., Scutellaria baicalensis Georgi, Rheum palmatum L., Coptis chinensis Franch., Phellodendron amurense Rupr., Gardenia jasminoides J. Ellis, and Paeonia lactiflora Pall | DSS-induced UC rats     | Reduce inflammatory factors and increased anti-inflammatory factors, alleviate histological changes in colon, inhibit the activation of NF-κB and ICAM-1 | [107]      |
| Modified Pulsatilla Decoction   | Radix Pulsatilae, Cortex Phellodendri, Rhizoma Coptidis, Cortex Fraxini, Sanchi, Radix Paeoniae Rubia, and Radix Glycyrrhiza | Oxazolone-induced UC mice | Inhibit the activation of NF-κB signaling pathway and reduce the severity of colitis                              | [108]      |
| Ampelopsis grossedentata        | A large amount of flavonoid active ingredients                              | DSS-induced UC mice     | Inhibit IRAK1/TRA6/NF-κB-mediated inflammatory signaling pathway, inhibit the elevated expression levels of TNF-α, IL-1β, IL-6 and IL-8 | [109]      |
| Guchang Zhixie Pill            | Coptidis Rhizoma, Zingiberis Rhizoma, Corydalis Rhizoma, Mume Fructus, Aucklandiae Radix and Papaveris Pericarpium | DSS-induced UC rats     | Inhibit the STAT3/NF-κB/IL-6 pathway, enrich in inflammation, immunity and oxidative stress-related pathways      | [110]      |
| Qingchang Wenzhong Decoction   | Coptis, Zingiber officinale Roscoe, rhizome, Indigo, sanguisorba carbon, wood, pseudoginseng and licorice | DSS-induced UC rats     | Decrease DAI, HS and MPO levels, down-regulate of IP10/CXCR3 axis-mediated inflammatory response                  | [113]      |
| Ershen Pill Extract            | Myristica Fragrans and Fructus Psoraleae                                   | Disorder-Diet-induced Pi yang deficiency diarrhea | Improve AQP3 synthesis in the colon                                                                                | [116]      |
| Costus root granules           | The extract of Costus root, ingredient dissolution into a traditional water decoction | TNBS-induced UC rats    | Inhibit the apoptosis of colonic epithelial cells, increase the expression of TGF-β, and activate the PI3K/AKT signaling pathway | [118]      |
| Xinhuang Tablets                | Herba Sarcandrae, Radix Notoginseng, Calculus Bovis and so on               | DSS-induced UC mice     | Reduce circulating levels of TNF-α and SAA, increase protein levels of TJs, and decrease phosphorylation levels of Elk-1 | [119]      |
| Composite Sophora Colon-Soluble Capsule | Radix Sophorae Flavescents, Indigo Naturalis, Bletilla striata, Radix Sanguisorbae, and Licorice Root | DSS-induced UC mice     | Restore gut microbiota, restore gut immune balance, reduce Th17 cell numbers, and increase the percentage of Treg cells | [120]      |
| Banxia Xiexin Decoction         | Rhizoma, Coptidis Rhizoma, Scutellariae Radix, Zingiberis Rhizoma, Ginseng Radix, Jujubae Fructus, and Glycyrrhiza Radix | TNBS-induced UC rats    | Anti-inflammatory                                                                                                   | [121]      |
| Ganjiang Decoction              | Zingiberis Rhizoma, Angelicae Sinensis Radix, Coptidis Rhizoma, Phellodendri Chinensis Cortex, Sanguisorbae Radix, Granati Pericarpium, and Asini Corii Cola | DSS-induced UC mice     | Improve DAI score, colon length, relative spleen weight, pathological analysis results, and inflammatory factors     | [122]      |
The classics of traditional Chinese medicine are summaries of the rich practical experience of physicians in the past dynasties, and they are the standard to guide the clinical practice of traditional Chinese medicine for thousands of years. By collecting and arranging medical records and herbal medicines of past dynasties, combined with folk prescriptions and prescriptions offered by famous doctors, traditional Chinese medicines and their compound prescriptions with apparent curative effect, wide clinical application, apparent characteristics, and advantages are sorted out. On this basis, the experimental research of screening traditional Chinese medicines with various pharmacological models is carried out, and modern multidisciplinary technology is used to reveal the pharmacodynamic material basis and molecular mechanism of traditional Chinese medicines and then promote the development of innovative traditional Chinese medicines and their application in clinical practice. For example, arsenic trioxide, developed from the traditional Chinese medicine arsenic for treating acute promyelocytic leukemia (APL), has a good effect [124]. The excavation and development of classic prescriptions is the entry point and breakthrough point for the inheritance and innovation of traditional Chinese medicine in the new era. The classic recipes derived from ancient books have thousands of years of human experience and are widely used in common diseases, frequently-occurring diseases, chronic diseases, and other fields. The research and development of classic prescriptions is a fast and effective transformation path, effectively filling the gaps in medical drugs for some chronic and intractable diseases. The commonly used CHMF originates from clinical practice and has experienced thousands of years of inheritance and practice. However, these CHMFs are challenging to be recognized by the public at home and abroad. For the widely used clinical prescriptions with exact curative effects, the world-recognized methods and scientific data are used to demonstrate their clinical efficacy and safety. Their clinical positioning is precise, which is conducive to the broader and more effective clinical use of traditional Chinese medicine.

The elucidation of the material basis of compound recipes is of great significance to the research on the mechanism of action of traditional Chinese medicine, quality control, new drug research, and new drug development. In recent years, modern scholars, based on the holistic view of traditional Chinese medicine, combined the spectrum-effect relationship of traditional Chinese medicine theory and bioinformatics to clarify the pharmacodynamic substances as well as their mechanism of action and achieved a transformation. Identify the pharmacodynamic substances, explain the interaction between CHMF and the body, and then use pharmacological methods to study the mechanism of action. Considering a single factor’s physical and chemical factors, the traditional Chinese medicine etiological animal model induced by biological damage, the Western medicine etiological and pathological animal model, and the clinical application characteristics of Chinese medicine cannot be well integrated. The researchers further established a disease-syndrome combination model to study the material basis and mechanism of CMHF. The combination of disease and syndrome model can reflect the characteristics of traditional Chinese medicine and be supported by the pathological changes and diagnostic evaluation of diseases in Western medicine. It is a trend in modern Chinese medicine research models. In this way, the pharmacodynamic material basis and mechanism of CHMF can be analyzed from the clinical point of view, the nature of the disease, and the overall composite level.

Acknowledgements
The study was supported by the Center for Chronic Disease Research at Dalian University College of Medicine and Yanbian University College of Pharmacy.

Author contributions
SY wrote the manuscript. QW collected the literature and wrote part of the manuscript. JL and J-CX collected the literature. YL, HM, and X-TH revised the manuscript. J-XN and Q-GZ presented the research ideas and revised the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by funds from the Korean Food Research Project (2017029) and the National Natural Science Foundation of China (61671098).

Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.

Author details
1. Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji 133002, Jilin, China. 2. Present Address: Chronic Disease Research Center, Medical College, Dalian University, Dalian 116622, Liaoning, China. 3. Department of Immunology and Pathogenic Biology, Yanbian University College of Basic Medicine, Yanji 133002, Jilin, China.

Received: 12 April 2022 Accepted: 2 June 2022 Published online: 18 June 2022

References
1. Al-Mustanjid M, Mahmud SMH, Royel MRI, Rahman MH, Islam T, Rahman I, et al. Chinese Medicine (2022) 17:74.
2. Ibrahim S, Zhu X, Luo X, Feng Y, Wang J. PLoS R2 regulates ZO-1 expression through the NF-kB pathway in inflammatory bowel disease. Int Immunopharmacol. 2020;85:106610.
3. Linon EA, Hanauer SB. Epidemiology of colorectal cancer in inflammatory bowel disease and systems biology approach. Genomics. 2020;112(5):3416–26.
4. Zeeshan M, Ali H, Khan S, Khan SA, Weigmann B. Advances in orally-delivered pH-sensitive nanocarrier systems: an optimistic approach for the treatment of inflammatory bowel disease. Int J Pharm. 2021;264:113280.
5. Li H. Advances in anti hepatic fibrotic therapy with traditional Chinese medicine herbal formula. J Ethnopharmacol. 2020;251:112442.
6. Luan X, Zhang LJ, Li XQ, Rahman K, Zhang H, Chen HZ, et al. Compound-based Chinese medicine formula: discovery from compatibility mechanism. J Ethnopharmacol. 2020;254:112687.
7. Gao W, Zhang L, Wang X, Yu L, Wang C, Gong Y. The combination of indirubin and isatin attenuates dextran sodium sulfate induced ulcerative colitis in mice. Biochem Biophys Res Commun. 2018;496(5):636–45.
8. Huang C, Dong J, Jin X, Ma H, Zhang D, Wang F, et al. Intestinal anti-inflammatory effects of fuzi-ganjiang herb pair against DSS-induced ulcerative colitis in mice. J Ethnopharmacol. 2020;261:112951.
9. Tang S, Liu W, Zhao Q, Li K, Zhu J, Yao W, et al. Combination of polysaccharides from Astragalus membranaceus and Codonopsis pilosula ameliorated mice colitis and underlying mechanisms. J Ethnopharmacol. 2021;264:113280.
10. Epple HJ, Zeitz M. HIV infection and the intestinal mucosal barrier. Ann N Y Acad Sci. 2012;1258:19–24.
11. Lee SH. Intestinal permeability regulation by tight junction: implication on inflammatory bowel diseases. Intest Res. 2015;13(1):11–8.
12. Takizawa Y, Kishimoto H, Tomita M, Hayashi M. Changes in the expression levels of tight junction components during reconstruction of tight junction from mucosal lesion by intestinal ischemia/reperfusion. Eur J Drug Metab Pharmacokinet. 2014;39(3):211–20.
13. Lin JC, Wu JQ, Wang F, Tang FY, Sun J, Xu B, et al. QingBai decoction regulates intestinal permeability of dextran sulphate sodium-induced colitis through the modulation of notch and NF-kappaB signalling. Cell Prolif. 2019;52(2):e12547.
14. Yuan Z, Yang L, Zhang X, Ji P, Hua Y, Wei Y. Huang-Lian-Jie-du decoction ameliorates acute ulcerative colitis in mice via regulating NF-kappaB and Nrf2 signaling pathways and enhancing intestinal barrier function. Front Pharmacol. 2019;10:1354.
15. Zou Y, Lin J, Liu W, Wu Z, He Z, Huang G, et al. Huangqin-tang ameliorates dextran sodium sulphate-induced colitis by regulating intestinal epithelial cell homeostasis, inflammation and immune response. Sci Rep. 2016;6:39299.
16. Fang W, Zhao P, Shen A, Liu L, Chen H, Chen Y, et al. Effects of Qing Hua Chloroform Yn on lippopolysaccharide induced intestinal epithelial tight junction injury in Caco2 cells. Mol Med Rep. 2021;23(3):1.
17. Lu Y, Lin H, Zhang J, Wei J, Sun J, Han L. Sijunzi decoction attenuates 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats and ameliorates TNBS-induced claudin-2 damage via NF-kappaB pathway in Caco2 cells. BMC Complement Altern Med. 2017;17(1):35.
18. Rodriguez-Pineiro AM, Bergstrom JH, Ermund A, Gustafsson JK, Schutte A, Johansson ME, et al. Studies of mucus in mouse stomach, small intestine, and colon. II. Gastrointestinal mucus proteome reveals Muc2 and Muc2ac accompanied by a set of core proteins. Am J Physiol Gastrointest Liver Physiol. 2013;305(5):G348–56.
19. Albert-Bayo M, Paracuellos I, Gonzalez-Castro AM, Rodriguez-Urrutia A, Rodriguez-Lagunas MJ, Alonso-Cotoner C, et al. Intestinal mucosal mast cells: key modulators of barrier function and homeostasis. Cells. 2019;8(2):135.
20. Muzes G, Tulassay Z, Sipos F. Interplay of autophagy and innate immunity in Crohn's disease: a key immunobiologic feature. World J Gastroenterol. 2013;19(28):4477–54.
21. Wang W, Chen L, Zhou R, Wang X, Song L, Huang S, et al. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. J Clin Microbiol. 2014;52(2):398–406.
22. Jiang H, Qu L, Dou R, Lu L, Bian S, Zhu W. Potential role of mesenchymal stem cells in alleviating intestinal ischemia/reperfusion impairment. PLoS ONE. 2013;8(9):e74468.
23. Yang Y, Chen G, Yang Q, Ye J, Cai X, Tsering P, et al. Gut microbiota drives the attenuation of dextran sulphate sodium-induced colitis by Huang-lian. PLoS ONE. 2017;12(8):e018637–4.
24. Yuan Z, Yang L, Zhang X, Ji P, Wei Y. Therapeutic effect of n-butanol fraction of Huang-lian-jie-du decoction on ulcerative colitis and its regulation on intestinal flora in colitis mice. Biomed Pharmacother. 2020;121:109638.
25. Zhang Z, Cao H, Shen P, Liu J, Cao Y, Zhang N. Pung.weixin alleviates chronic colitis in mice by regulating intestinal microbiota composition. J Ethnopharmacol. 2020;255:112715.
26. Liu P, Bian Y, Liu T, Zhong J, Zhong Y, Zhan S, et al. Huai hua san alleviates dextran sulphate sodium-induced colitis and modulates colonic microbiota. J Ethnopharmacol. 2020;259:112944.
27. Yang M, Bose S, Lim SK, Kim H. Preventive effects of Pyung-wi-san against dextran sulphate sodium- and Clostridium difficile-induced inflammatory bowel disease in mice. Int J Mol Sci. 2019;20(24):6346.
28. Singh N, Gurav A, Sivaparakasam S, Brady E, Padia R, Shi H, et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity. 2014;40(1):128–39.
29. de Pieter V. Metabolomics in the clinical diagnosis of inflammatory bowel disease. Adv Drug Deliv Rev. 2015;73:33(Suppl 1):1–20.
30. Bottcher T, Pitscheider M, Sieber SA. Natural products and their biological targets: proteomic and metabolomic labeling strategies. Angew Chem Int Ed Engl. 2010;49(15):2680–98.
31. Dehais J, Derau R, Rueda-Rincon N, Swinnen JV. Lipidomics in drug development. Drug Discov Today Technol. 2015;13:33–8.
32. Hong ZC, Cai Q, Wu HZ, Yang YF, Fan H, Duan XY. Compound Sophorae decoction: treating ulcerative colitis by affecting multiple metabolic pathways. Chin J Nat Med. 2021;19(4):267–83.
33. Han Z, Wang H, Guo D, Zhang J. Integrative transcriptomic and metabonomic profiling analyses reveal the molecular mechanism of Chinese traditional medicine huankuile suspension on TNBS-induced ulcerative colitis. Aging. 2021;13(9):1007–10.
34. Yuan Z, Yang L, Zhang X, Ji P, Hua Y, Wei Y. Mechanism of Huang-lian-Jie-du decoction and its effective fraction in alleviating acute ulcerative colitis in mice: regulating arachidonic acid metabolism and glycerophospholipid metabolism. J Ethnopharmacol. 2020;259:112872.
35. Wang D, Ma X, Guo S, Wang Y, Li T, Zou D, et al. Effect of Huangqin Tang on urine metabolic profile in rats with ulcerative colitis based on UPLC-Q-exact orbitrap MS. Evid Based Complement Alternat Med. 2020;2020:1874065.
36. Wang D, Shi K, Wang Y, Zou D, Guo S, Li T, et al. Effect of Huangqin Tang on colonic gene expression in rats with ulcerative colitis. Int J Genom. 2020;2020:2438757.
37. Luo S, Wen R, Wang Q, Zhao Z, Nong F, Fu Y, et al. Rhubarb Peony decoction ameliorates ulcerative colitis in mice by regulating gut microbiota to restoring Th17/Treg balance. J Ethnopharmacol. 2019;231:39–49.
38. Amagase K, Kimura Y, Wada A, Yukishige T, Murakami T, Nakamura E, et al. Prophylactic effect of monosodium glutamate on NSAID-induced enteropathy in rats. Curr Pharm Des. 2020;16(10):2783–90.
39. Chen F, Yin YT, Zhao HM, Wang HY, Zhong YB, Long J, et al. Sishen pill treatment of DSS-induced colitis via regulating interaction with inflammatory dendritic cells and gut microbiota. Front Physiol. 2020;11:801.
40. Ma H, Tao W, Zhu S. T lymphocytes in the intestinal mucosa: defense and tolerance. Cell Mol Immunol. 2019;16(3):216–24.
41. Zhong YB, Kang ZP, Zhou BG, Wang HY, Long J, Zhu W, et al. Cucurmin regulated the homeostasis of memory T cell and ameliorated dextran sulfate sodium-induced experimental colitis. Front Pharmacol. 2020;11:630244.
42. Wu B, Wan Y. Molecular control of pathogenic Th17 cells in autoimmune diseases. Int Immunopharmacol. 2020;80:106187.
43. Tanoue T, Atashari K, Honda K. Development and maintenance of intestinal regulatory T cells. Nat Rev Immunol. 2016;16(5):295–309.
44. Haase S, Haghikia A, Wilck N, Muller DN, Linker RA. Impacts of microbiota-associated cancer. Cell Mol Gastroenterol Hepatol. 2015;1(1):6–16.
45. Zhao Y, Luan H, Jiang H, Xu Y, Wu X, Zhang Y, et al. Gegen Qinlian decoction alleviates experimental colitis via suppressing TLR4/NF-kappaB signaling and enhancing antioxidant effect. Phytomedicine. 2016;23(10):1012–20.
46. Liu B, Biao X, Niu W, Zhang Q, Ma C, Wu T, et al. Kuijeyuan decoction improved intestinal barrier injury of ulcerative colitis by affecting TLR4-dependent PI3K/AKT/NF-kappaB oxidative and inflammatory signaling and gut microbiota. Front Pharmacol. 2020;11:1036.
47. Zhou HY, Zhu H, Yao XM, Qian JP, Yang J, Pan XD, et al. Metformin regulates tight junction of intestinal epithelial cells via MLCK-MLC signaling pathway. Eur Rev Med Pharmacol Sci. 2017;21(22):5329–46.
48. Xiong Y, Wang C, Shi L, Wang L, Zhou Z, Chen D, et al. Myosin light chain kinase: a potential target for treatment of inflammatory diseases. Front Pharmacol. 2017;8:292.
49. Xiang J, Jia M, Zhao L, Zhang S. Bu-Zhong-Yi-Qi granule enhances colonic tight junction integrity via TLR4/NF-kappaB/MLC signaling pathway in ulcerative colitis rats. Evid Based Complement Alternat Med. 2021;2021:6657141.
50. Chao L, Li Z, Zhou J, Chen W, Li Y, Lu W, et al. Shen-Ling-Bai-Zhu-San improves dextran sulfate sodium-induced colitis by inhibiting caspase-1/caspase-11-mediated pyroptosis. Front Pharmacol. 2020;11:814.
51. Wieacker P, Zimmerman J, Ropers HH. X inactivation patterns with probable X-linked dominant, male lethal inheritance. Clin Genet. 2013;83(2):146–53.
52. Brett BK, Pinksky BA, Erikson RL. Nlk is a murine protein kinase related to Erk/MAP kinases and localized in the nucleus. Proc Natl Acad Sci USA. 1998;95(3):963–8.
53. Ota S, Ishitani S, Shimizu N, Matsumoto K, Itoh M, Ishitani T. NLK positively regulates Wnt/beta-catenin signalling by phosphorylating LEF/TCF1 in neural progenitor cells. EMBO J. 2012;31(8):1004–15.
54. Wang HY, Zhao HM, Wang Y, Li X, Xu X, Li X, et al. Sisen pill on Tiff cells in mice with experimental colitis. Front Physiol. 2020;11:589.
55. Waldner MJ, Neurath MF. Mechanisms of immune signaling in colitis-associated cancer. Cell Mol Gastroenterol Hepatol. 2015;1(1):6–16.
56. Perkins ND. Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene. 2006;25(51):6717–30.
57. Li F, Zhang J, Arfuso F, Chinnaiah B, Avedov ME, Alharbi SA, et al. NF-kappaB in cancer therapy. Arch Toxicol. 2013;87(9):711–31.
58. He Z, Zhou Q, Wen K, Wu B, Sun X, Wang X, et al. Huangkui Lianchang decoction alleviates DSS-induced ulcerative colitis in mice by inhibiting the Th17/Treg cell homeostasis via suppressing IL-6/JAK2/STAT3 signaling. J Ethnopharmacol. 2020;251:112549.
59. Xu M, Duan XY, Chen QY, Fan H, Hong ZC, Deng SJ, et al. Effect of compound soupsode decoction on dextran sulfate sodium (DSS)-induced colitis in mice by regulating Th17/Treg cell balance. Biomed Pharmacother. 2019;109:2396–408.
60. Wen J, Teng B, Yang P, Chen X, Li C, Jing Y, et al. The potential mechanism of Bawei Xileisan in the treatment of dextran sulfate sodium-induced ulcerative colitis in mice. J Ethnopharmacol. 2016;188:31–8.
61. Liu XQ, Zhao HM, Wang HY, Ge W, Zhong YB, Long J, et al. Regulatory effect of Sischen pill on Tiff cells in mice with experimental colitis. Front Physiol. 2020;11:589.
62. Vandenberg MR, Neurath MF. Immunobiology of nuclear factor kappaB in cancer therapy. Arch Toxicol. 2015;89(5):711–31.
63. Li S, Wu Y, Yang D, Wu C, Ma C, Liu X, et al. Gastric in D peripheral myeloid cells drives neuroinflammation in experimental autoimmune encephalomyelitis. J Exp Med. 2019;12(11):2562–81.
64. Zhao W, He F, Barkema HW, Xu S, Gao J, Liu G, et al. Prototheca spp induce an inflammatory response via mtrOS-mediated activation of NF-kappaB and NLRP3 inflammasomes in bovine mammary epithelial cell cultures. Vet Res. 2021;52(1):144.
65. Qiao H, Huang Y, Chen Y, Yang L, Wang Y, Xu R. Jaweiheqao decoction alleviates DSS-induced ulcerative colitis via inhibiting inflammation. Gastroenterol Res Pract. 2020;2020:7182874.
66. Zhang Z, Shen P, Xie W, Cao H, Liu J, Cao Y, et al. Pingwei San ameliorates dextran sulfate sodium-induced chronic colitis in mice. J Ethnopharmacol. 2019;236:91–9.
67. Alkhatad H, Macluskey M, White S, Ellis I. Nerve growth factor-induced migration in oral and salivary gland tumour cells utilises the PI3K/AKT signalling pathway: is there a link to perineural invasion? J Oral Pathol Med. 2020;49(3):227–34.
68. Gabbouj S, Ryhanen S, Marttinnen M, Wirttahrin R, Takalo M, Kemppainen S, et al. Altered insulin signaling in Alzheimer's disease brain—special emphasis on PI3K/Akt pathway. Front Neurosci. 2019;13:5629.
69. Zhou BG, Liu FC, Zhao HM, Zhang XY, Wang HY, Li DY. Regulatory effect of Zuoqin pill on correlation with gut microbiota and Treg cells in DSS-induced colitis. J Ethnopharmacol. 2020;262:113211.
70. Ge W, Wang HY, Zhao HM, Liu X, Zhong YB, Long J, et al. Effect of Sischen pill on memory T cells from experimental colitis induced by dextran sulfate sodium. Front Pharmacol. 2020;11:908.
71. Wang B, Gong Z, Zhan J, Yang L, Zhou Q, Yuan X. Xianguan pill suppresses inflammation and protects intestinal epithelial barrier by promoting autophagy in DSS-induced ulcerative colitis mice. Front Pharmacol. 2020;11:594847.
72. Li MY, Luo HJ, Wu X, Liu YH, Gan YX, Xu N, et al. Anti-inflammatory effects of Huangqin decoction on dextran sulfate sodium-induced ulcerative colitis in mice through regulation of the gut microbiota and suppression of the Ras-PI3K/Akt-HIF-1alpha and NF-kappaB pathways. Front Pharmacol. 2019;10:1552.
73. Leonard WJ, O'Shea JJ. Jak's and STATs: biological implications. Annu Rev Immunol. 1998;16:293–322.
81. Hiller J, Haegl B, Effner F, Ruel A, Schaller M, Mascher B, et al. STAT1 gain-of-function and dominant negative STAT3 mutations impair IL-17 and IL-22 immunity associated with CMC. J Invest Dermatol. 2018;138(3):711–4.

82. Li X, Wang Y, Wang K, Wu Y. Renal protective effect of paoniflorin by inhibition of JAK2/STAT3 signaling pathway in diabetic mice. Biosci Trends. 2018;12(2):168–76.

83. Lu Z, Xiong W, Xiao S, Lin Y, Yu K, Yue G, et al. Huanglian Jiedu decotion ameliorates DSS-induced colitis in mice via the JAK2/STAT3 signalling pathway. Chin Med. 2020;15:45.

84. Li L, Shen A, Chu J, Sferra TJ, Sankararaman S, Ke X, et al. Pien Tze Huang ameliorates DSS-induced colonic inflammation in a mouse colitis model through inhibition of the IL-6/STAT3 pathway. Mol Med Rep. 2018;18(1):1113–9.

85. Xuan-Qing C, Xiang-Yu LV, Shi-Jia LIU. Baitouweng decoction alleviates dextran sulfate sodium-induced ulcerative colitis by regulating intestinal microbiota and the IL-6/STAT3 signaling pathway. J Ethnopharma... (Full text not visible)

86. Foldi J, Chung AY, Xu H, Zhu J, Outtz HH, Kitajewski J, et al. Autoamplification of Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol. 2006;7(9):678–89.

87. Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol. 2006;7(9):678–89.

88. Wu H, Chen QY, Wang WZ, Chu S, Liu XX, Liu YJ, et al. Compound sopho... (Full text not visible)

89. Lea SR, Reynolds SL, Kaur M, Simpson KD, Hall SR, Hessel EM, et al. The... (Full text not visible)

90. Corr M. Wnt signaling in ankylosing spondylitis. Clin Rheumatol. 2014;33(6):579–62.

91. Sharma M, Castro-Piedras I, Simmons GE Jr, Pruitt K. Dishevelled: a gain-of-function and dominant negative STAT3 mutations impair... (Full text not visible)

92. Zhu H, Li YR. Oxidative stress and redox signaling mechanisms of the OSMR pathway and improving gut microbiota. Phytomedicine. 2021;80:153372.

93. Verstockt S, Verstockt B, Machiels K, Vancamelbeke M, Ferrante M, et al. Oncostatin M is a biomarker of diagnosis, worse disease... (Full text not visible)

94. Wang X, Li D, Zhang Y, Wu S, Tang F. Costus root granules improve macrophage lysosomes in chronic colitis rats. Ann Palliat Med. 2021;10(2):2203–16.

95. Li Y, Chen F, Xie Y, Yang Q, Luo H, Jia P, et al. Feiyangchangweiyan capsule protects against ulcerative colitis by bidirectionally modulating dysregulated Notch signaling. Phytomedicine. 2020;68:153182.

96. Verstockt S, Verstockt B, Machiels K, Vancamelbeke M, Ferrante M, et al. Oncostatin M is a biomarker of diagnosis, worse disease... (Full text not visible)

97. Zhu H, Li YR. Oxidative stress and redox signaling mechanisms of the OSMR pathway and improving gut microbiota. Phytomedicine. 2021;80:153372.

98. Zhang W, Chao X, Wu JQ, Ma XB, Yang YL, Wu Y, et al. Exploring the potential mechanism of Gungui Xixue Wan for treating ulcerative colitis by comprehensive network pharmacological approaches and molecular docking validation as well as cell experiments. Chem Biodivers. 2021(1): e2000810.

99. Jimbo K, Ohtsuka Y, Kojima Y, Hosoi K, Obahayashi N, Ikuse T, et al. Increased expression of CCKAR3 axis components and matrix metalloproteinase in inflammatory bowel disease patients. Pediatr Int. 2014;56(6):873–83.

100. Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO, et al. CXC10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev. 2011;22(3):121–30.

101. Mao TY, Shi R, Zhao WH, Guo Y, Gao KL, Chen C, et al. Qingchang Wenzhou decoction ameliorates dextran sulphate sodium-induced ulcerative colitis in rats by downregulating the IP10/CXCR3 axis-mediated inflammatory response. Evid Based Complement Alternat Med. 2018;2014:4312598.

102. Kreida S, Roche JV, Olsson C, Linse S, Tornroth-Horsefield S. Protein–protein interactions in AQPs of the AQP0-CAM and AQP2-LIPS complex formation. Faraday Discuss. 2018;209:35–54.

103. Berga G. Water channel proteins (later called aquaporins) and relatives: present, past, and future. IUBMB Life. 2009;61(2):112–33.

104. Pan X, Xu K, Xiong R, Chen ZM, Hu CJ, Feng J, et al. Therapeutic effect of Enshen pill (extract from P (spleen)-Shen (kidney) yang deficiency-induced diarrhea in rat model. Chin J Integr Med. 2019;25(7):536–42.

105. Sun B, Yuan J, Wang S, Lin J, Zhang W, Shao J, et al. Qingchang suppository ameliorates colonic vascular permeability in dextran-sulfate-sodium-induced ulcerative colitis. Front Pharmacol. 2018;9:1235.

106. Wang X, Li D, Zhang Y, Wu S, Tang F. Costus root granules improve ulcerative colitis through regulation of TGF-beta mediation of the PI3K/AKT signaling pathway. Exp Ther Med. 2018;15(5):4477–84.

107. Wu M, Shen A, Chen Y, Liu L, Li L, Sankararaman S, et al. Xinhuang tablets improve intestinal barrier function via regulating epithelial tight junctions in dextran sulfate sodium-induced ulcerative colitis mice. J Ethnopharmacol. 2021;241(1):33–9.

108. Ding Y, Chen M, Wang Q, Gao L, Feng Y, Wang S, et al. Integrating pharmacology and microbial network analysis with experimental validation to reveal the mechanism of complex sorophia colon-soluble capsule against ulcerative colitis. Evid Based Complement Alternat Med. 2020;2020:9521073.

109. Wang W, Xu C, Li X, Wang Z, Yang J, Shen Y, et al. Exploration of the potential mechanism of Banxia Xiein decoction for the effects on TNBS-induced ulcerative colitis rats with the assistance of network pharmacology analysis. J Ethnopharmacol. 2021;177:114197.
122. Wei Y, Jiang N, Liu T, Liu C, Xiao W, Liang L, et al. The comparison of extraction methods of ganjiang decoction based on fingerprint, quantitative analysis and pharmacodynamics. Chin Med. 2020;15:81.

123. Buchner AM, Schneider Y, Lichtenstein GR. Biosimilars in inflammatory bowel disease. Am J Gastroenterol. 2021;116(1):45–56.

124. Zhu HH, Hu J, Lo-Coco F, Jin J. The simpler, the better: oral arsenic for acute promyelocytic leukemia. Blood. 2019;134(7):597–605.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.